Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2014 - 2026)

Cumberland Pharmaceuticals has disclosed Gains from Investment Securities across 9 years of filings, most recently posting -$228965.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$228965.0, down 609.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $164370.0 (down 59.26% YoY), and the FY2025 annual result was $438311.0, up 242.33% from the prior year.
• Gains from Investment Securities came in at -$228965.0 for Q1 2026 at Cumberland Pharmaceuticals, down from $345082.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.1 million in Q4 2023 to a low of -$983574.0 in Q3 2022.
• The 5-year median for Gains from Investment Securities is -$208969.0 (2023), against an average of $27211.9.
• Across the five-year window, Gains from Investment Securities soared 119.52% in 2025 and slumped 609.08% in 2026, its largest moves.
• Cumberland Pharmaceuticals' Gains from Investment Securities stood at $1.1 million in 2022, then grew by 5.45% to $1.1 million in 2023, then dropped by 5.54% to $1.1 million in 2024, then plunged by 67.57% to $345082.0 in 2025, then plunged by 166.35% to -$228965.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$228965.0 (Q1 2026), $345082.0 (Q4 2025), and $9651.0 (Q3 2025), per Business Quant data.